Download - Radiation oncology
![Page 1: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/1.jpg)
Radiation Oncology
![Page 2: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/2.jpg)
“What’s the big deal about radiotherapy in cancer clinical trial design?”
![Page 3: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/3.jpg)
![Page 4: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/4.jpg)
The treatment of cancer with ionising radiation is called Radiotherapy (RT) or Radiation Oncology.
180º310º
217º
External RT + Intensity Modulated Radiotherapy (IMRT)
Brachytherapy
Radiosurgery - Stereotactic RT
Particle therapy with
Protons or light ionsPhillipe Lambin
![Page 5: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/5.jpg)
The Evolution of Radiation The Evolution of Radiation TherapyTherapy
High resolution IMRTMultileaf Collimator
Dynamic MLCand IMRT
1960’s1960’s 1970’s1970’s 1980’s1980’s 1990’s1990’s2000’s2000’s
Cerrobend BlockingElectron Blocking
Blocks were used to Blocks were used to reduce the dose to reduce the dose to normal tissuesnormal tissues
MLC leads to 3D MLC leads to 3D conformal therapy conformal therapy which allows the first which allows the first dose escalation trials.dose escalation trials.
Computerized IMRT Computerized IMRT introduced which introduced which allowed escalation of allowed escalation of dose and reduced dose and reduced compilationscompilations
Functional Functional ImagingImaging
IMRT Evolution IMRT Evolution evolves to smaller evolves to smaller and smaller and smaller subfields and high subfields and high resolution IMRT resolution IMRT along with the along with the introduction of new introduction of new imaging imaging technologiestechnologies
The First ClinacComputerized 3D CT Treatment Planning
Standard Collimator
The linac reduced The linac reduced complications complications compared to Co60compared to Co60
![Page 6: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/6.jpg)
Eff
ect
Tumor Dose
Tumor control
Effect of underdosage and overdosage
Late normal tissue damage
![Page 7: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/7.jpg)
Multidisciplinary decision: Treatment
protocol
The clinical side: workflow in Radiation Oncology
Treatment:
- Irradiation
- QA dose
- QA set-up (Imaging)
Prostaat AP(1-1-2002 tot 1-1-2003)
0
10
20
30
40
50
60
Afwijking (%)
Aa
nta
l
meetresultaat
Follow-up
*Baardwijk van A, et al. Int J Radiat Oncol Biol Phys.
Treatment Preparation:
- Contact MD-patient
- Simulation (imaging)
- Tumour delineation*
- 3D Planning
Phillipe Lambin
![Page 8: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/8.jpg)
Trials of Radiation Therapy Alone
• Target Volume
• Organs at Risk
• Quality Assurance• Dose
• Volume
• Time
• Assessment of Toxicities
![Page 9: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/9.jpg)
ICRU 62 report
… and Margins: The irradiated volumes
•GTV = Gross Tumour Volume= Macroscopic tumour
•CTV = Clinical Target Volume= Microscopic tumour
•PTV = Planning target Volume
PTV
Advice: Always use the ICRU reports to specify
and record dose and volumeBaumert et al. IJROBP 2006 Sep 1;66(1):187-94
![Page 10: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/10.jpg)
Interpretation of radiotherapy Interpretation of radiotherapy trials:trials:
Radiotherapy outcomes are Radiotherapy outcomes are dependent upon dependent upon technicaltechnical factors factors
Advice: Always perform Quality Advice: Always perform Quality Assurance (QA) & particularly in Assurance (QA) & particularly in
phase III trialsphase III trialsPhillipe Lambin
![Page 11: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/11.jpg)
Quality Control-Radiation
• Standard time, dose, and fractionation schedules
• Specify fields or target volumes – be precise• Specify doses to target volumes• IMRT vs. 3-D conformal radiotherapy• CT-based vs. conventional simulation• Field verification• Dose inhomogeneity
![Page 12: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/12.jpg)
0 20 40 60 80 100 120 140 160 180
10
15
20
25
30
35
40
5-y
ear
su
rviv
al
(%)
SER (days)
De Ruysscher et al. J Clin Oncol. 2006 Mar 1;24(7):1057-63.)
Treatment Time: Treatment Time:
the SER the SER (Start of any treatment to End of Radiation)(Start of any treatment to End of Radiation)
Phillipe Lambin
![Page 13: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/13.jpg)
![Page 14: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/14.jpg)
Quality Control-Radiation
• Standard dose and fractionation schedules• Specify fields or target volumes – be precise• Specify doses to target volumes
• IMRT vs. 3-D conformal radiotherapy• CT-based vs. conventional simulation• Field verification• Dose inhomogeneity
![Page 15: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/15.jpg)
Multi-leaf Collimator
![Page 16: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/16.jpg)
Multileaf Collimator in LINAC
![Page 17: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/17.jpg)
IMRT
•As the treatment head arcs, “leaves open and close to control the amount of radiation given in each “beam’s eye view.”
•This creates the ability to tightly sculpt dose.
![Page 18: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/18.jpg)
![Page 19: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/19.jpg)
Image-guidance: The Next Generation
![Page 20: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/20.jpg)
Advances in Radiation Therapy - The New Pyramid
EarlyPeriod
CurrentPeriod
GTV
Normal Tissue
Precise localizationGeographic miss
BTV
![Page 21: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/21.jpg)
Advances in Radiation Therapy - The Pyramid
EarlyPeriod
CurrentPeriod
GTV
Normal Tissue
Precise localizationGeographic miss
![Page 22: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/22.jpg)
CTV CTV
PTVPTV
WithoutImaging
WithImaging
CTV – volume containing diseasePTV – volume that needs to be irradiated to ensure CTV is always treated
Objectives of IGRT & Dynamic Targeting
![Page 23: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/23.jpg)
![Page 24: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/24.jpg)
![Page 25: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/25.jpg)
Multi-Modality Radiation Trials
![Page 26: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/26.jpg)
Translation to the Clinic -Potential Problems
• Baseline response rate
• Baseline cure rate
• Baseline toxicity
• Interdependence of one modality on the other for therapeutic effect
• Competing risks for end-point of interest
![Page 27: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/27.jpg)
Factors Affecting Radiation Sensitivity
• Intrinsic Factors • Ras mutational status
• EGFR
• DNA repair capabilities
• DNA methylation
• Extrinsic Factors• Tumor microenvironment – hypoxia
• pH
• Tumor vasculature – ‘normalization’
![Page 28: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/28.jpg)
Cell Cycle
![Page 29: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/29.jpg)
Radiobiologic principles of therapy. An understanding of the radiobiology that governs the interaction of ionizing radiation with living matter is the key to improving the therapeutic ratio in radiation oncology. A, Varying levels of
sensitivity to radiation. It has been well known for decades that there are varying levels of sensitivity to radiation depending on the phase of the cell cycle that
malignant cells are in when treatment occurs. (Adapted from Sinclair)/www.lungcancerslides.com
![Page 30: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/30.jpg)
0.01
0.1
1
0 1 2 3 4 5 6
ControlNelfinavir
Su
rviv
ing
fra
cti
on
DOSE (GY)
Radiation Survival Curve
DMF = ratio of doses that give a particular level of cell kill
![Page 31: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/31.jpg)
![Page 32: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/32.jpg)
Chemoradiotherapy
• An improved therapeutic index should be the goal • Effect of chemoradiotherapy on the tumor compared to
the effect of chemoradiotherapy on normal tissue toxicity
• Classically there are 4 ways to define the interaction– spatial cooperation– toxicity independence– radioprotectors– radiation sensitizers
– Steel & Peckham IJROBP 5:85, 1979
![Page 33: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/33.jpg)
Eff
ect
Tumor Dose
Tumor control
Therapeutic Gain
Late normal tissue damage
![Page 34: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/34.jpg)
Seiwert T, Salama T, Vokes E; Nat Clin Pract Oncol. 2007 Feb; 4(2):86-100
![Page 35: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/35.jpg)
Preclinical Studies-Rationale
• Combining chemotherapy with radiation requires a rationale preferably grounded in supporting preclinical data
• There should be convincing preclinical data that indicates that the combination is either
• Efficacious (radiation sensitization)
• No overlapping toxicities (toxicity independence)
![Page 36: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/36.jpg)
Preclinical Studies-Rationale
• Demonstrate in vitro radiosensitization in human tumor cell lines
• Demonstrate in vivo radiosensitization in human tumor models
• Demonstrate the lack of sensitization of normal tissues
• Preclinical studies should use clinically relevant doses and schedules of agents & XRT
![Page 37: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/37.jpg)
Question # 1
![Page 38: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/38.jpg)
Question # 2
![Page 39: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/39.jpg)
Phase I Studies of Drugs and Radiation
![Page 40: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/40.jpg)
Phase I studies-Endpoints
• The goals of combined modality Phase I studies are similar to single agent studies
• However, the design and application often differs
• The primary endpoint is usually an assessment of toxicity with the goal of identifying a recommended Phase II dose
![Page 41: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/41.jpg)
Phase I studies
• The definition of the recommended Phase II dose: the doses and schedules of both the drug and radiation when used in combination
• It is NOT the same as the maximally tolerated dose although MTD can be used to identify the recommended Phase II dose
• The schedule and dose of radiation may be very different from that used with each agent alone
![Page 42: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/42.jpg)
Phase I studies
• Data helpful for the design of the study– Single agent pharmacokinetic data from the
relevant scheduling regimen– Continuous dosing during XRT vs. once a week dosing
– Single agent pharmacodynamic data– Agent’s affect on a molecular target that is relevant to
the interaction between XRT and radiation
– Single agent safety data
![Page 43: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/43.jpg)
Phase I studies-Design Issues
• Patient selection– What tumor sites?
– The answer to this question impacts greatly upon the assessment of toxicity.
– The selection of tumor site may also be impacted by the agent being used in combination with XRT (think C225 and HNC)
– Curative or palliative radiotherapy?– This will affect total radiation dose and fractionation– This will affect the patient population and perhaps the ability
to tolerate combined modality therapy
– In general, Phase I data are generated from studies that are cancer-specific and/or site-specific.
![Page 44: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/44.jpg)
Phase I studies-Design Issues
• What doses and schedules of the agent should be selected?
• If the goal is radiosensitization, then delivery of the agent during as many fractions of radiation is desirable
• The schedule and dose may also be impacted by the known characteristics and target of the agent
• What doses of radiation should be selected?• A typical approach especially in the curative setting is to
start with a standard radiation dose; however escalation of the radiation dose may be desirable in certain clinical situations
![Page 45: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/45.jpg)
Phase I studies-Design Issues
• A limited dose-escalation design is typical for these studies
• Dose-limiting toxicity rules• Grade IV hematological toxicity
• Grade III non-hematological toxicity
• Exceptions should be considered – Grade III diarrhea in the setting of upper abdominal XRT
• Breaks during XRT
![Page 46: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/46.jpg)
Phase I studies-Design Issues
• Dose escalation rules• Standard Phase I dose escalation rules are
acceptable especially if multiple agents are being used (including conventional chemotherapy)• Consider using a toxicity assessment in
association with clinical or biological endpoints• Particularly with targeted agents, defining the
“optimal biologic dose” might be appropriate• Be careful because the biological endpoint is a
surrogate for clinical efficacy and this may not be known during the Phase I development period
![Page 47: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/47.jpg)
Phase I studies-Endpoints
• Toxicity criteria• Consider XRT or combined modality-specific criteria
(RTOG)
• Toxicity assessment is typically during the entire radiation course and some defined period of time after XRT, e.g. 30 days
• How do we assess late effects?• There are practical and time limitations
• Bevacizumab and thoracic radiation
![Page 48: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/48.jpg)
![Page 49: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/49.jpg)
Phase I studies-Design Issues
• Think about the next step in development– What is the standard therapy for the tumor
site being treated?– What is the role of conventional
chemotherapy?– How should surgery (if appropriate) be
integrated?– How should chemotherapy be integrated?
![Page 50: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/50.jpg)
Anti-Angiogenic Therapy
• Hypothesis: Can anti-angiogenic therapy augment the effect of radiation therapy and chemotherapy on rectal cancer?
• Immature and inefficient blood vessels could be pruned by eliminating excess endothelial cells --> “Normalized Vasculature” --> Improved delivery of nutrients and therapeutics
![Page 51: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/51.jpg)
Day 0 - Abnormal
Day 1 and 2 – Normalized
Normal
Day 5 - Inadequate
Jain, Nature Medicine (2001)
Normalization Hypothesis
Tong et al. (2003)
VEGF Blockade Normalizes Tumor Vasculature
![Page 52: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/52.jpg)
806040200
0.00
0.25
0.50
0.75
1.00
Radiation Dose, Gy
Tu
mo
r c
on
tro
l p
rob
abil
ity
RAD
+ 1/2mAb
+ mAb
66.2
54.8
39.1
(59.6-73.6)
(45.1-66.6)
(31.7-48.1)
TCD , Gy50
(95% CI)
54A
RAD
+ 1/2mAb
+ mAb
97.8 (85.3-112.0)
86.3 (74.6-99.8)
74.8 (63.7-87.7)
1401201008060402000
U87
Anti-VEGF-R2 mAb enhances radiation therapy
Kozin et al. Cancer Research (2001)
RAD+ 1/2mAb+ mAb
(95% CI)TCD , Gy50
![Page 53: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/53.jpg)
Antiangiogenic therapy: Conclusions from Preliminary In- vivo Data
• The addition of antiangiogenic agents to chemoradiation programs: – increases tumor perfusion/reduces hypoxia– increases tumor radioresponse• does not appear to increase (skin) toxicity
– increases chemoresponse
![Page 54: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/54.jpg)
Phase I Study
Bevacizumab
Bevacizumab
EBRT 5-FU
SURGERY
cT3 or T4 Rectal Ca
7 weeks
![Page 55: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/55.jpg)
Rectal Cancer: Phase I Study (Schema)
Bevacizumab 5-10 mg/kg, 2 weeks prior to XRT
Level Bev (q2wk) 5-FU (mg/m2/d) RT (Gy)
1 5 mg/kg 225 50.4
2 10 mg/kg 225 50.4
Bevacizumab: 4 Infusions
After determination of MTD, 20 additional pts to be treated
Willett et al. Nature Medicine, 2004
![Page 56: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/56.jpg)
Study Endpoints / Correlates
• MTD of Bevacizumab with EBRT and 5-FU• Preliminary Data: pCR, LC, PFS, S • Correlative studies– Functional imaging (PET, CT perfusion studies)
– Interstitial Pressure Measurement
– Circulating Endothelial Cells and Precursors
– Tissue
– Serum and Urine
![Page 57: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/57.jpg)
Endoscopic IFP Measurements
Pt3 Pt4 Pt5 Pt6
Mean IFP before and 12 days afterthe first AVASTIN infusion
Inte
rsti
tial
flu
id p
ress
ure
(m
mH
g)
Bars- SE, p<0.05
**
*
*
![Page 58: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/58.jpg)
Copyright © American Society of Clinical OncologyBrown, A. P. et al. J Clin Oncol; 26:3987-3994 2008
Proposed clinical trial design to evaluate
targeted agents in combination
with radiation or other cytotoxic
therapies
![Page 59: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/59.jpg)
Phase II studies
• The decision to proceed with a combined modality Phase II study is dependent upon the safety and early efficacy results from the Phase I trial
• The primary goals of a Phase II combined modality study is efficacy
![Page 60: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/60.jpg)
Phase II trials-Endpoints
• Response rates are often not helpful for selecting efficacious regimens
• Delayed time to response with XRT
• Residual unevaluable masses vs. scarring
• Progressive disease outside of the XRT field
• Underlying high local response rates to XRT
![Page 61: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/61.jpg)
Phase II trials-Endpoints
• Consider other efficacy endpoints• Complete response rate
• Pathological complete response rate
• Local or locoregional control rates
• Time to progression
• Survival
• The endpoint selected will depend upon the tumor & the current standard therapy
![Page 62: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/62.jpg)
Phase II trials-Endpoints
• Additional toxicity data both acute and late toxicity are essential components
• Collection of late toxicity data in the larger group of patients that constitutes a Phase II study will be helpful as the Phase III study is designed
![Page 63: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/63.jpg)
Phase II trials-Design
• Early stopping rules for toxicity (most likely acute toxicity) should be considered
• Early stopping rules for low response rates compared to historical controls may also be a useful design consideration
• Usually dramatic differences in response must be seen for early stopping rules to be implemented
![Page 64: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/64.jpg)
Phase III Study
• Generally a major interdependence of modalities
• Quality control of each modality can be of enormous importance in defining whether a therapy should be used
• Produces an interaction which can effect the study outcome
![Page 65: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/65.jpg)
Special Considerations in trials that include surgical therapy
• The surgeon as a prognostic factor• Adherence to surgical technique
• Quality control
• Experience of the surgeon
• The pathologist as a variable• Quality control
![Page 66: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/66.jpg)
![Page 67: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/67.jpg)
![Page 68: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/68.jpg)
COMBINED MODALITY THERAPY
• One must consider multiple issues in study design– Biologic interaction between modalities– Patient selection– Quality control– Base line data- response, toxicity, survival
• The same issues as in other studies,but approached differently
![Page 69: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/69.jpg)
![Page 70: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/70.jpg)
![Page 71: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/71.jpg)
![Page 72: Radiation oncology](https://reader034.vdocuments.site/reader034/viewer/2022051108/545591c4af7959d2368b69d6/html5/thumbnails/72.jpg)
Acknowledgements
• Stephen Hahn, MD
• Clifton D. Fuller, MD
• Joseph Rajendran, MD
• Todd Scarbrough, MD